Clinical Trials and Research News Weekly Roundup | S2 E28 | Favipiravir Cut while Ivermectin Added

TrialSite News Weekly roundup

Delhi’s #COVID-19 Provider Lok Nayak Hospital Cuts #Favipiravir & Adds Ivermectin & Remdesivir for COVID-19 Patients: Lok Nayak Hospital is the national capital’s first COVID-19 only facility. Although Favipiravir was recently embraced in India by Glenmark Pharmaceuticals in the form of Fabiflu, this Delhi hospital has discontinued the use of the drug for COVID-19 patients. The well-known hospital has approved off label use of #Ivermectin for early-stage COVID-19 patients, as well as #Remdesivir, Tocilizumab, and plasma therapy.

Prominent Brazilian University Embarks on Phase 2 Ivermectin Clinical Trial: The Federal University of Sao Carlos, (UFSCar) a public research university located in Sao Carlos, in the state of Sao Paulo Brazil was established in 1968 and supports the education of over 15,000 undergraduates and about 4,700 graduate students. Ranked among the top 10 universities in Brazil, the Brazilian Ministry of Education assigned UFSCar a maximum teaching quality score. The university just initiated a Phase 2 clinical trial investigating Ivermectin as a therapeutic treatment against SARS-CoV-2. 13

Promising COVID Treatments Emerging From Israel Includes Ivermectin: Scientists across the globe are working on vaccines to prevent Covid-19 infection. But in the meanwhile, and even after initial vaccines are approved, there is an urgent need for effective treatments for the respiratory disease caused by the SARS-CoV-2 coronavirus. The following list is of 13 potential Israeli treatments using a variety of approaches – such as Ivermectin, placenta-derived cells, peptides, blood plasma of recovered patients, and the cannabis compound CBD.

More Evidence for Hydroxychloroquine as a Life-Saver; CNN Casts Doubts: As we reported July 3, a Henry Ford Health System retrospective found a significant reduction in death for those treated with hydroxychloroquine over a non-treated group. Another recent study, not yet peer reviewed, is found on PrePrints. Published online July 3 and titled, “COVID-19 Outpatients – Early Risk-Stratified Treatment with Zinc Plus Low Dose Hydroxychloroquine and Azithromycin: A Retrospective Case Series Study,” the paper looks at 141 severe COVID-19 patients who received “the triple therapy”: zinc, low-dose HCQ, and azithromycin. Findings included that 2.8% of the treated group were hospitalized, compared with 15.4% for the control group. The Conclusion notes that “treatment of COVID-19 outpatients as early as possible after symptom onset with the used triple therapy, including the combination of zinc with low dose hydroxychloroquine, was associated with significantly less hospitalizations and 5 times less all-cause deaths.”